StockData

Gossamer Bio vs Gyre Therapeutics

GOSS and GYRE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GOSS and GYRE compare

Gossamer Bio is the larger company, worth 11 times as much as Gyre Therapeutics ($5.4B against $508M).

Gossamer Bio grew revenue faster over the last twelve months (32.4% versus −3.7% for Gyre Therapeutics).

Gyre Therapeutics keeps more of each dollar of sales as profit, with a net margin of −33.9% compared with −235% at Gossamer Bio.

Gyre Therapeutics scores higher on the StockData Score (11 against 1 for Gossamer Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGOSSGYRE
Size and price
Market cap$5.4B$508M
Share price$11.04$4.56
Change, 1 year−94.9%−42.9%
Change, 5 years−98.7%−75.7%
Beta (5Y)2.331.21
Employees161618
StockData Score
Total score111 (better)
Valuation score01 (better)
Growth score11
Performance score03 (better)
Health score06 (better)
Dividend score00
Valuation
P/S101×4.7× (better)
P/B–4.7×
FCF yield−3.0%−1.5% (better)
Fair value–$5.29
Margin of safety–13.8%
Growth
Revenue growth (TTM)32.4% (better)−3.7%
Revenue growth, 5Y average–41.0%
Net income growth (TTM)–−801%
Profitability
Gross margin–93.4%
Operating margin−312%−14.4% (better)
Net margin−235%−33.9% (better)
FCF margin−305%−7.2% (better)
Return on equity–−34.9%
Return on invested capital–−26.6%
Financial health
Debt / equity–0.00
Interest coverage−15.2×–
Current ratio0.534.32 (better)
Altman Z-score−15.268.53 (better)
Piotroski F-score15 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions0.98%7.8%
Held by insiders2.8%93.8%
Insider net buying, 12 months–−$953K
Superinvestors holding1–
Short interest, % of float0.28%32.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.